Court Upholds One Gemzar Patent, Lilly Appeals on Second Patent

Eli Lilly has won a federal court decision affirming patent protection on its cancer treatment Gemzar until later this year, but the court declined to uphold a second patent that would have protected the drug until 2013. Lilly’s ’614 patent on Gemzar (gemcitabine HCl), which was being challenged by Sicor Pharmaceuticals, is valid, and Sicor is enjoined from marketing a generic version of the drug until the patent expires Nov. 15, the U.S. District Court for the Southern District of Indiana ruled recently.
Generic Line